000			02393naa a2200181uu 4500
001			10760
003			OSt
005			20190211155148.0
008			030204s2005 xx ||||gr |0|| 0 eng d
100	1		_aWIKTOROWICZ, Mary E _911351
245	1	0	_aShifting priorities at the health protection branch : _bchallenges to the regulatory process
260			_cdec. 2002
520	3		_aThe Health Protection Branch (HPB) of Health Canada has recently undergone considerable policy and organizational renewal, with numerous and broadranging implications for the evaluation of drug product safety and efficacy. From a public-health perspective, howeverm the criteria used to develop organizational and policy change at the HPB have provided a sub-optmal basis for reform, due primarily to the many forms of market failure to which the regulation of pharmaceuticals is subject. for example, the partnership and efficiency criteria that guided policy renewal have led to the transfer of important responsibilities to partners, with the potential for either a conflict of interst or inadequate information, for which the legal basis is not always clear. The resulting realignment of the HPB' s roles and responsibilities may be characterized as leading to a shift from a comprehensive approach to public-health protection to one based on strategic risk management, with responsibilities dispersed among government, industry, academia and consumers. The rebalancing of goals in the redesign of the regulatory process suggests a change in the role of the state in the context of public-health protection and highlights issues of concern to the public interest that may not be fully recognized a deregulation occurs in other sectors of the economy
773	0	8	_tAustralian Journal of Public Administration _g61, 4, p. 1-22 _d, dec. 2002 _w
942			_cS
998			_a20030204 _bLucima _cLucimara
998			_a20060727 _b1549^b _cQuiteria
999			_aConvertido do Formato PHL _bPHL2MARC21 1.1 _c10885 _d10885
041			_aeng